Jazz Pharmaceuticals plc
NASDAQ:JAZZBiotechnology
+$0.05 today
- Market cap
- $15.90B
- Beta
- 0.33
- P/E (TTM)
- 476.3
- EPS (TTM)
- $0.48
Volume 0.72M
Average 0.92M
JAZZ Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Jazz Pharmaceuticals plcNASDAQ: JAZZ
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables turns positive
Q3 FY2026 accounts receivables was $79.4M, compared with -$51M a year earlier. Trailing-twelve-month accounts receivables was -$37.81M. Over 3 fiscal years it compounded at +5.6% a year.
Context
- Accounts receivables amounted to 2.5% of revenue in FY2025, up 2.0 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $79.4M or moves back toward the trailing-twelve-month quarterly average of -$9.45M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (106.28M) USD
- Year-over-year change
- -403.3%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (106.28M) | -403.3% |
| FY2024 | 2024-12-31 | (21.12M) | +59.3% |
| FY2023 | 2023-12-31 | (51.88M) | +42.4% |
| FY2022 | 2022-12-31 | (90.14M) | +2.8% |
| FY2021 | 2021-12-31 | (92.74M) | — |
Accounts Receivables vs competitors
How JAZZ compares with its peers on the latest reported figures
- JAZZ's LTM Sep 2026 accounts receivables of $37.81M is the 6th largest of the 9 companies compared; the peer median is $138.44M.
- Its year-over-year change of -4.5% is the 7th highest of 8, against a peer median of +103.5%.
- Accounts receivables amounts to 0.8% of revenue for JAZZ, versus a peer median of 5.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $282.32M | +167.9% | +81.5% | 4.9% | |
| LTM Sep 2026 | $197.5M | -20.0% | +9.1% | 5.3% | |
| LTM Jun 2026 | $189.32M | — | -57.2% | 4.6% | |
| LTM Sep 2026 | $151.44M | +1.2% | — | 16.9% | |
| LTM Sep 2026 | $125.44M | +174128.2% | — | 9.2% | |
| LTM Sep 2026 | $37.81M | -4.5% | +5.6% | 0.8% | |
| LTM Jun 2026 | $25.84M | +513.3% | — | 8.9% | |
| LTM Jun 2026 | $18.01M | +83.4% | -11.6% | 1.9% | |
| LTM Mar 2026 | $117K | +103.5% | -41.7% | 0.1% | |
| Peer median (excluding JAZZ) | $138.44M | +103.5% | -11.6% | 5.1% | |
Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (329.67M) | (224.06M) | 414.83M | 560.12M | (356.15M) |
| Depreciation & Amortization | 552.48M | 629.47M | 638.7M | 660.07M | 696.3M |
| Deferred Income Tax | 69.2M | (292.25M) | (260.22M) | (208.33M) | (444.97M) |
| Stock-Based Compensation | 189.01M | 222M | 226.84M | 248.05M | 291.13M |
| Change in Working Capital | (47.95M) | 9.91M | (204.44M) | (76.72M) | 18.9M |
| Accounts Receivables | (92.74M) | (90.14M) | (51.88M) | (21.12M) | (106.28M) |
| Inventory | (48.86M) | (49.64M) | (13.42M) | (45.54M) | (86.04M) |
| Accounts Payables | 57.02M | (11.23M) | 9.6M | (20.07M) | 39.85M |
| Other Working Capital | 36.62M | 160.91M | (148.74M) | 10.01M | 171.37M |
| Other Non-Cash Items | 345.44M | 926.92M | 276.29M | 212.72M | 1.15B |
| Operating Cash Flow | 778.51M | 1.27B | 1.09B | 1.4B | 1.36B |
| Capital Expenditures | (45.53M) | (498.19M) | (23.96M) | (48.07M) | (209.75M) |
| Acquisitions (Net) | (6.23B) | 53M | 0 | 0 | (858.05M) |
| Purchases of Investments | (26.82M) | (61.04M) | (390.1M) | (1.31B) | (1.83B) |
| Sales of Investments | 1.1B | 60M | 270M | 845M | 1.36B |
| Other Investing Activities | (17.89M) | 0 | (19M) | (10M) | (122.83M) |
| Investing Cash Flow | (5.21B) | (446.23M) | (163.06M) | (508.2M) | (1.51B) |
| Debt Repayment | 3.87B | (582.01M) | (31M) | 374.77M | (781M) |
| Common Stock Issued | 135.26M | 0 | 46.46M | 20.65M | 107.86M |
| Common Stock Repurchased | 0 | (54K) | (269.76M) | (311.43M) | (125.02M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (35.6M) | (45.44M) | (50.95M) | (63.47M) | (75.22M) |
| Financing Cash Flow | 3.97B | (529.49M) | (305.25M) | 20.52M | (873.38M) |
| Effect of Forex Changes | (3.21M) | (6.22M) | 1.14M | (1.68M) | 6.56M |
| Net Change in Cash | (466.32M) | 290.03M | 624.83M | 906.55M | (1.02B) |
| Free Cash Flow | 732.98M | 773.78M | 1.07B | 1.35B | 1.15B |
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
Intrinsic Alpha fair value
Locked
Current Price
$247.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.